"label","id","instanceType","uuid:ID","rationale","description","name"
"","StudyDesign_1","StudyDesign","a183e1dd-a39e-40a6-bd5a-30df39316c50","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1"
